Yi‐Hsiang Huang

This study identifies microbial and metabolic changes across the adenoma-carcinoma sequence in colorectal cancer using 16S rRNA sequencing and metabolomic profiling.

The paper evaluates the clinical impact of pharmacogenetic risk variants in a large Han Chinese cohort, finding that while most carry risk variants, the excess risk of adverse events is small and most patients do not experience adverse outcomes.

This study identifies clinical and molecular features of primary refractoriness to atezolizumab plus bevacizumab in HCC, showing poor outcomes and an immunosuppressive tumor microenvironment.